drugset / Trial / NCT02982694
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
Phase 2
Terminated
46 enrolled
Vall d'Hebron Institute of Oncology
European Organisation for Research and Treatment of Cancer - EORTC · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to determine the anti-tumor activity, as measured by overall response rate (ORR) of atezolizumab in combination with bevacizumab in patients with chemotherapy resistant CRC and positivity for MSI-like molecular signature. This is an international, open-label single arm (non-randomized), one-stage phase II trial.
Timeline
- Start
- 2017-11-24
- Primary completion
- 2020-11-27
- Completion
- 2020-11-27
Outcome
Outcome not reported
Stopped: “The results of the interim analysis showed that the efficacy in the MSS subgroup (MSI like) is inferior to the expected, and this situation is very unlikely to be reversed if the trial is fully completed.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |